Developer docs
API playgroundTry for free, no card

Search company profiles

OneSource

Full company profile

uuid006hg7b

Namestring
OneSource
Legal namestring
OneSource Specialty Pharma Limited
Company typeenum
Public
Founded yearint
1990
Descriptiontext

OneSource Specialty Pharma Limited is a publicly listed Indian specialty pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services across four core technology platforms: drug-device combinations, complex injectables, biologics (microbial and mammalian cell line), and soft gelatin capsules. The company was established in 2021 as a Strides Pharma Group initiative under founder Arun Kumar and completed its IPO on Indian exchanges (BSE and NSE) in January 2025. Headquartered in Bengaluru with five state-of-the-art manufacturing facilities approved by FDA, MHRA, ANVISA, TGA, WHO and MCC, OneSource serves global pharmaceutical and biotechnology companies seeking integrated drug substance and drug product manufacturing under a single quality system. The company employs over 1,600 professionals including more than 100 techno-commercial experts, with named customers including Dr. Reddy's, Hikma, Formycon, Xbrane Biopharma and Orbicular.

The company's technical capabilities span high-concentration biologic formulations via the HILOPRO platform (licensed from Bhami Research Lab, validated across six commercial molecules at 100-250 mg/mL), drug-device combination assembly across 9 device formats with 20+ flexible assembly stations, lyophilization using QbD-led PAT-driven cycles, and integrated GLP-1 peptide formulation and analytical development. Infrastructure includes 550,000 ft² of dedicated biologics manufacturing space, capacity to produce 2.4 billion softgel capsules annually, and over 20 automatic and semi-automatic assembly lines for prefilled syringes, pen injectors and autoinjectors. The company tracks 35 approved ANDAs, 40+ commercialized US products and 200+ regulatory inspections cleared, including 18 in the past 24 months.

OneSource generates revenue through project-based CDMO contracts and commercial manufacturing services, with pricing not publicly disclosed and determined by scope, volume and complexity. The go-to-market is direct B2B enterprise sales supported by techno-commercial experts, event-driven engagement at industry conferences such as CPHI Frankfurt, and a content library of technical whitepapers and webinars. Customer segments are horizontally split between enterprise pharmaceutical companies (primary) and biotechnology companies (primary), with secondary use cases in GLP-1 and peptide therapeutics developers and biosimilar developers. Distribution is entirely B2B with no retail or consumer channels, and the customer base spans the United States, India, the United Kingdom, Canada, Brazil and Saudi Arabia. Leadership is drawn from major pharma companies including Ranbaxy, Sun Pharma, Steriscience, Moderna, Roche, Syngene and Fujifilm Diosynth.

Short descriptiontext

OneSource Specialty Pharma is an Indian publicly listed specialty pharmaceutical CDMO providing end-to-end development and manufacturing services across drug-device combinations, complex injectables, biologics, and soft gelatin capsules to global pharmaceutical and biotechnology companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersBengaluru, India
HQ citystring
Bengaluru
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical CDMO services, drug-device combinations, complex sterile injectables, biologics manufacturing, soft gelatin capsules
Industry4 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

Full-service CDMO providing end-to-end development and manufacturing services across multiple technology platforms. Revenue generated through project-based contracts for drug development, analytical services, and commercial manufacturing. Services span early-stage development through commercialization and lifecycle management.

onesourcecdmo.com
2Commercial Manufacturing
TypeHardware Sales
Description

Manufacturing services for approved drug products including sterile injectables, biologics, drug-device combinations, and soft gelatin capsules. Revenue from commercial supply of drug products.

onesourcecdmo.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

OneSource Specialty Pharma is a multimodal specialty pharmaceutical CDMO (Contract Development and Manufacturing Organization) that provides end-to-end drug development and manufacturing services across four core technology platforms: Drug-Device Combinations, Complex Injectables, Biologics, and Soft Gelatin Capsules. The company offers integrated pharmaceutical services from early-stage formulation development through analytical characterization, GMP manufacturing, regulatory support, and commercial supply. Services are delivered to global pharmaceutical and biotech clients through five state-of-the-art facilities in Bengaluru, India, approved by FDA, MHRA, ANVISA, TGA, WHO, and MCC.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 35 approved ANDAs and 19 commercialized drug products in the United States
+3 more records
Product overview1 text field

OneSource Specialty Pharma is a multimodal specialty pharmaceutical CDMO (Contract Development and Manufacturing Organization) offering end-to-end capabilities across four core technology platforms: Drug-Device Combinations, Complex Injectables, Biologics, and Soft Gelatin Capsules. The company provides integrated services from early-stage development through commercialization, encompassing formulation development, analytical characterization, GMP manufacturing, and regulatory support. Key offerings include the HILOPRO formulation platform for high-concentration subcutaneous biologics, GLP-1 peptide development services, lyophilization services, and advanced analytical characterization. With five state-of-the-art facilities in Bengaluru, India, OneSource serves pharmaceutical and biotech companies globally seeking integrated CDMO partnerships.

Product and service8 records
1Drug-Device Combinations
CategoryContract Manufacturing - Drug-Device Combinations
Description

Comprehensive development and manufacturing of specialized drug-device combination products including prefilled syringes with/without safety devices, dial and push variable/fixed dose pen injectors, pull push fixed dose pens, and autoinjectors. Currently handling 9 device platforms/formats for pharmaceutical and biotech clients.

2Complex Injectables (Sterile Injectables)
CategoryContract Manufacturing - Sterile Injectables
Description

Development and manufacturing of complex sterile injectables including sterile liquids, lyophilized vials, prefilled syringes, and dry powder injections with over 25 years of domain experience. Backed by 35 approved ANDAs and 19 commercialized drug products in the United States.

3Biologics CDMO Services
CategoryContract Manufacturing - Biologics
Description

End-to-end biologics solutions including development and manufacture of microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products with integrated drug substance and drug product cGMP manufacturing. Supported by 550,000 ft² of biologics manufacturing space.

4Soft Gelatin Capsules
CategoryContract Manufacturing - Soft Gelatin Capsules
Description

Mastery in soft gelatin capsule technologies including traditional softgels, enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories with capacity of 2.4 billion capsules annually across versatile shapes and sizes.

5HILOPRO Formulation Platform
CategoryTechnology Platform - High-Concentration Biologics Formulation
Description

High-concentration formulation platform for subcutaneous biologics delivery that solves the concentration-viscosity challenge, enabling protein concentrations of 100-250 mg/mL while maintaining syringeability. Patented by Bhami Research Lab, accessed by OneSource through strategic partnership, validated across six commercial molecules.

6GLP-1 Peptide Development Services
CategoryService Offering - GLP-1 Peptide Therapeutics Development
Description

Integrated formulation and analytical development for GLP-1 peptide therapeutics including stability optimization, solubility enhancement, aggregation control, viscosity management, and device compatibility for diabetes and obesity treatments.

7Lyophilization Services
CategoryService Offering - Lyophilization Technology
Description

Development, optimization, scale-up and transfer of lyophilization cycles for challenging formulations including QbD-led approach with PAT-driven endpoints and thermal characterization for scalable, regulatory-ready freeze-drying processes.

8Analytical Characterization Services
CategoryService Offering - Analytical and Bioanalytical Testing
Description

Advanced analytical characterization including LC-MS, SEC-MALS, surface plasmon resonance (SPR), peptide mapping, cell-based bioassays, and stability-indicating methods for defining Critical Quality Attributes and supporting CMC documentation.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-07-14
Description

Strategic manufacturing partnership for biosimilars. OneSource will provide manufacturing capabilities for Formycon's biosimilar pipeline targeting global markets.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-11
Description

Partnership to commercialize generic version of Ozempic (Semaglutide Injection) in Saudi Arabia. OneSource provides manufacturing and regulatory support.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-11
Description

Biosimilars manufacturing partnership for global markets. OneSource and Xbrane collaborate on development and manufacturing of biosimilar products.

Strategic tierCoreTypeTechnology or Integration
Description

Strategic partnership giving OneSource access to the HILOPRO formulation platform, a patented high-concentration biologic formulation technology validated across six commercial molecules.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CDMO partnership where OneSource supports Dr. Reddy's manufacturing needs. Dr. Reddy's received Health Canada Approval for Generic Semaglutide Injection with OneSource's support.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Orbicular's Partner secured tentative U.S. ANDA approval for generic Ozempic with OneSource as CDMO partner providing manufacturing support.

Strategic tierMinorTypeOthers
Description

Provided fairness opinion for the Composite Scheme of Arrangement and Amalgamation (Merger by Absorption) in 2025.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Switzerland-based global CDMO leader across biologics, small molecules, and cell & gene therapies. Comparable in CDMO business model and biologics/drug product capabilities, but at substantially larger scale and broader geographic footprint.

2Syngene International
TypeDirect peer
Description

India-based publicly listed CDMO offering end-to-end drug discovery, development, and manufacturing services across small molecules and biologics. Direct comparable in geography, scale, and integrated CDMO model serving global pharma and biotech customers.

TypeBroad incumbent
Description

China-based global CDMO offering end-to-end services across small molecules, biologics, and cell/gene therapies. Comparable in integrated CDMO model and biologics capabilities, though operating in a different geography.

TypeDirect peer
Description

India-based pharmaceutical company with CDMO operations across sterile injectables, APIs, and radiopharmaceuticals. Direct comparable in injectables and biologics contract manufacturing.

TypeDirect peer
Description

India-based CDMO offering discovery, development, and manufacturing services for small molecules and biologics. Comparable in geographic footprint, full-service CDMO model, and biotech/pharma customer base.

TypeDirect peer
Description

India-based CDMO focused on contract development and manufacturing of APIs and intermediates. Comparable in India-based operations serving global pharma customers, though more concentrated in small molecules.

TypeDirect peer
Description

India-headquartered CDMO with capabilities across sterile injectables, biologics, and oral solids; competes directly with OneSource in complex injectables and drug substance/drug product integration for global pharma customers.

TypeEmerging player
Description

India-based vertically integrated pharmaceutical company with growing injectable and biosimilar manufacturing capabilities. Comparable in sterile injectables and biosimilars development focus, though primarily a generic manufacturer rather than pure-play CDMO.

TypeDirect peer
Description

India-based pharmaceutical company with a growing CDMO segment offering API, formulation, and biologics services. Comparable in geographic base, customer profile, and integrated CDMO capabilities.

TypeBroad incumbent
Description

US-headquartered global CDMO with leading positions in softgel capsules, sterile injectables, and biologics drug product. Closely comparable in softgel (OneSource produces 2.4B capsules/year) and drug-device combination capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OneSource

Pharmaceutical Contract Development and Manufacturing (CDMO)onesourcecdmo.com

OneSource Specialty Pharma is an Indian publicly listed specialty pharmaceutical CDMO providing end-to-end development and manufacturing services across drug-device combinations, complex injectables, biologics, and soft gelatin capsules to global pharmaceutical and biotechnology companies.

What OneSource does

OneSource Specialty Pharma Limited is a publicly listed Indian specialty pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services across four core technology platforms: drug-device combinations, complex injectables, biologics (microbial and mammalian cell line), and soft gelatin capsules. The company was established in 2021 as a Strides Pharma Group initiative under founder Arun Kumar and completed its IPO on Indian exchanges (BSE and NSE) in January 2025. Headquartered in Bengaluru with five state-of-the-art manufacturing facilities approved by FDA, MHRA, ANVISA, TGA, WHO and MCC, OneSource serves global pharmaceutical and biotechnology companies seeking integrated drug substance and drug product manufacturing under a single quality system. The company employs over 1,600 professionals including more than 100 techno-commercial experts, with named customers including Dr. Reddy's, Hikma, Formycon, Xbrane Biopharma and Orbicular.

The company's technical capabilities span high-concentration biologic formulations via the HILOPRO platform (licensed from Bhami Research Lab, validated across six commercial molecules at 100-250 mg/mL), drug-device combination assembly across 9 device formats with 20+ flexible assembly stations, lyophilization using QbD-led PAT-driven cycles, and integrated GLP-1 peptide formulation and analytical development. Infrastructure includes 550,000 ft² of dedicated biologics manufacturing space, capacity to produce 2.4 billion softgel capsules annually, and over 20 automatic and semi-automatic assembly lines for prefilled syringes, pen injectors and autoinjectors. The company tracks 35 approved ANDAs, 40+ commercialized US products and 200+ regulatory inspections cleared, including 18 in the past 24 months.

OneSource generates revenue through project-based CDMO contracts and commercial manufacturing services, with pricing not publicly disclosed and determined by scope, volume and complexity. The go-to-market is direct B2B enterprise sales supported by techno-commercial experts, event-driven engagement at industry conferences such as CPHI Frankfurt, and a content library of technical whitepapers and webinars. Customer segments are horizontally split between enterprise pharmaceutical companies (primary) and biotechnology companies (primary), with secondary use cases in GLP-1 and peptide therapeutics developers and biosimilar developers. Distribution is entirely B2B with no retail or consumer channels, and the customer base spans the United States, India, the United Kingdom, Canada, Brazil and Saudi Arabia. Leadership is drawn from major pharma companies including Ranbaxy, Sun Pharma, Steriscience, Moderna, Roche, Syngene and Fujifilm Diosynth.

OneSource firmographics

Firmographics
Name
OneSource
Legal name
OneSource Specialty Pharma Limited
Website
https://onesourcecdmo.com
Company type
Public
Founded year
1990
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
OneSource Specialty Pharma is an Indian publicly listed specialty pharmaceutical CDMO providing end-to-end development and manufacturing services across drug-device combinations, complex injectables, biologics, and soft gelatin capsules to global pharmaceutical and biotechnology companies.
Ownership category
akta.pro rank

OneSource industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Pharmaceutical CDMO services
  • Drug-device combinations
  • Complex sterile injectables
  • Biologics manufacturing
  • Soft gelatin capsules

Where OneSource is headquartered

Location

Headquarters

HQ city
Bengaluru
HQ country
India
HQ region
Asia

Offices3 records

Markets served

OneSource business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Development and Manufacturing Services: Full-service CDMO providing end-to-end development and manufacturing services across multiple technology platforms. Revenue generated through project-based contracts for drug development, analytical services, and commercial manufacturing. Services span early-stage development through commercialization and lifecycle management.
  2. Commercial Manufacturing: Manufacturing services for approved drug products including sterile injectables, biologics, drug-device combinations, and soft gelatin capsules. Revenue from commercial supply of drug products.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

OneSource product offering

Product offering

Core offering

OneSource Specialty Pharma is a multimodal specialty pharmaceutical CDMO (Contract Development and Manufacturing Organization) that provides end-to-end drug development and manufacturing services across four core technology platforms: Drug-Device Combinations, Complex Injectables, Biologics, and Soft Gelatin Capsules. The company offers integrated pharmaceutical services from early-stage formulation development through analytical characterization, GMP manufacturing, regulatory support, and commercial supply. Services are delivered to global pharmaceutical and biotech clients through five state-of-the-art facilities in Bengaluru, India, approved by FDA, MHRA, ANVISA, TGA, WHO, and MCC.

Product overview

OneSource Specialty Pharma is a multimodal specialty pharmaceutical CDMO (Contract Development and Manufacturing Organization) offering end-to-end capabilities across four core technology platforms: Drug-Device Combinations, Complex Injectables, Biologics, and Soft Gelatin Capsules. The company provides integrated services from early-stage development through commercialization, encompassing formulation development, analytical characterization, GMP manufacturing, and regulatory support. Key offerings include the HILOPRO formulation platform for high-concentration subcutaneous biologics, GLP-1 peptide development services, lyophilization services, and advanced analytical characterization. With five state-of-the-art facilities in Bengaluru, India, OneSource serves pharmaceutical and biotech companies globally seeking integrated CDMO partnerships.

Differentiator

Problem solved

Functional benefit

Products and services

  • Drug-Device Combinations Comprehensive development and manufacturing of specialized drug-device combination products including prefilled syringes with/without safety devices, dial and push variable/fixed dose pen injectors, pull push fixed dose pens, and autoinjectors. Currently handling 9 device platforms/formats for pharmaceutical and biotech clients.
  • Complex Injectables (Sterile Injectables) Development and manufacturing of complex sterile injectables including sterile liquids, lyophilized vials, prefilled syringes, and dry powder injections with over 25 years of domain experience. Backed by 35 approved ANDAs and 19 commercialized drug products in the United States.
  • Biologics CDMO Services End-to-end biologics solutions including development and manufacture of microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products with integrated drug substance and drug product cGMP manufacturing. Supported by 550,000 ft² of biologics manufacturing space.
  • Soft Gelatin Capsules Mastery in soft gelatin capsule technologies including traditional softgels, enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories with capacity of 2.4 billion capsules annually across versatile shapes and sizes.
  • HILOPRO Formulation Platform High-concentration formulation platform for subcutaneous biologics delivery that solves the concentration-viscosity challenge, enabling protein concentrations of 100-250 mg/mL while maintaining syringeability. Patented by Bhami Research Lab, accessed by OneSource through strategic partnership, validated across six commercial molecules.
  • GLP-1 Peptide Development Services Integrated formulation and analytical development for GLP-1 peptide therapeutics including stability optimization, solubility enhancement, aggregation control, viscosity management, and device compatibility for diabetes and obesity treatments.
  • Lyophilization Services Development, optimization, scale-up and transfer of lyophilization cycles for challenging formulations including QbD-led approach with PAT-driven endpoints and thermal characterization for scalable, regulatory-ready freeze-drying processes.
  • Analytical Characterization Services Advanced analytical characterization including LC-MS, SEC-MALS, surface plasmon resonance (SPR), peptide mapping, cell-based bioassays, and stability-indicating methods for defining Critical Quality Attributes and supporting CMC documentation.

Quantifiable outcome

  • 35 approved ANDAs and 19 commercialized drug products in the United States
  • +3 more outcomes

Companies that use OneSource

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

OneSource technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

OneSource partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Formycon AGcoreStrategic or Co-development Partner · 14 July 2026Strategic manufacturing partnership for biosimilars. OneSource will provide manufacturing capabilities for Formycon's biosimilar pipeline targeting global markets.
  • HikmacoreStrategic or Co-development Partner · 11 February 2026Partnership to commercialize generic version of Ozempic (Semaglutide Injection) in Saudi Arabia. OneSource provides manufacturing and regulatory support.
  • Xbrane BiopharmacoreStrategic or Co-development Partner · 11 June 2025Biosimilars manufacturing partnership for global markets. OneSource and Xbrane collaborate on development and manufacturing of biosimilar products.
  • Bhami Research LabcoreTechnology or IntegrationStrategic partnership giving OneSource access to the HILOPRO formulation platform, a patented high-concentration biologic formulation technology validated across six commercial molecules.
  • Dr. Reddy's LaboratoriescoreStrategic or Co-development PartnerCDMO partnership where OneSource supports Dr. Reddy's manufacturing needs. Dr. Reddy's received Health Canada Approval for Generic Semaglutide Injection with OneSource's support.
  • OrbicularcoreStrategic or Co-development PartnerOrbicular's Partner secured tentative U.S. ANDA approval for generic Ozempic with OneSource as CDMO partner providing manufacturing support.
  • ICICI SecuritiesminorOthersProvided fairness opinion for the Composite Scheme of Arrangement and Amalgamation (Merger by Absorption) in 2025.

Scale indicators12 records

Recent moves10 records

Expansion highlights5 records

OneSource competitors and assessment

Company assessment

Broad incumbents

  • Lonza Group: Switzerland-based global CDMO leader across biologics, small molecules, and cell & gene therapies. Comparable in CDMO business model and biologics/drug product capabilities, but at substantially larger scale and broader geographic footprint.
  • WuXi AppTec / WuXi STA: China-based global CDMO offering end-to-end services across small molecules, biologics, and cell/gene therapies. Comparable in integrated CDMO model and biologics capabilities, though operating in a different geography.
  • Catalent: US-headquartered global CDMO with leading positions in softgel capsules, sterile injectables, and biologics drug product. Closely comparable in softgel (OneSource produces 2.4B capsules/year) and drug-device combination capabilities.

Direct peers

  • Syngene International: India-based publicly listed CDMO offering end-to-end drug discovery, development, and manufacturing services across small molecules and biologics. Direct comparable in geography, scale, and integrated CDMO model serving global pharma and biotech customers.
  • Jubilant Pharmova: India-based pharmaceutical company with CDMO operations across sterile injectables, APIs, and radiopharmaceuticals. Direct comparable in injectables and biologics contract manufacturing.
  • Sai Life Sciences: India-based CDMO offering discovery, development, and manufacturing services for small molecules and biologics. Comparable in geographic footprint, full-service CDMO model, and biotech/pharma customer base.
  • Suven Pharmaceuticals: India-based CDMO focused on contract development and manufacturing of APIs and intermediates. Comparable in India-based operations serving global pharma customers, though more concentrated in small molecules.
  • Piramal Pharma Solutions: India-headquartered CDMO with capabilities across sterile injectables, biologics, and oral solids; competes directly with OneSource in complex injectables and drug substance/drug product integration for global pharma customers.
  • Laurus Labs: India-based pharmaceutical company with a growing CDMO segment offering API, formulation, and biologics services. Comparable in geographic base, customer profile, and integrated CDMO capabilities.

Emerging players

  • Aurobindo Pharma: India-based vertically integrated pharmaceutical company with growing injectable and biosimilar manufacturing capabilities. Comparable in sterile injectables and biosimilars development focus, though primarily a generic manufacturer rather than pure-play CDMO.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

OneSource social profiles

Digital presence

OneSource compliance and trust

Trust signal

Compliance6 records

OneSource financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OneSource leadership team

Management profile

Number of profiles

Profiles15 records

OneSource subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

OneSource funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OneSource M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OneSource

What does OneSource do?

OneSource Specialty Pharma is a multimodal specialty pharmaceutical CDMO (Contract Development and Manufacturing Organization) that provides end-to-end drug development and manufacturing services across four core technology platforms: Drug-Device Combinations, Complex Injectables, Biologics, and Soft Gelatin Capsules. The company offers integrated pharmaceutical services from early-stage formulation development through analytical characterization, GMP manufacturing, regulatory support, and commercial supply. Services are delivered to global pharmaceutical and biotech clients through five state-of-the-art facilities in Bengaluru, India, approved by FDA, MHRA, ANVISA, TGA, WHO, and MCC.

Is OneSource a public or private company?

OneSource is a public company. It is classified as public and is currently operating.

When was OneSource founded?

OneSource was founded in 1990. It employs 1,001 to 5,000 people.

Where is OneSource based?

OneSource is headquartered in Bengaluru, India, in the Asia region.

How does OneSource make money?

Two revenue lines are on record. Contract Development and Manufacturing Services are the primary driver. The others are commercial Manufacturing.

Who are OneSource's main competitors?

Broad incumbents on record are Lonza Group, WuXi AppTec / WuXi STA and Catalent. Direct peers are Syngene International, Jubilant Pharmova, Sai Life Sciences, Suven Pharmaceuticals, Piramal Pharma Solutions and Laurus Labs. Aurobindo Pharma is listed as an emerging player.

Does OneSource have an API?

No public API is recorded for OneSource.

What industry is OneSource in?

OneSource's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScanXOneSource Specialty Pharma CQO Bernhard Thurnbauer resigns effective Nov 17OneSource Specialty Pharma announced Chief Quality Officer Bernhard Thurnbauer's resignation effective November 17, 2026, due to personal relocation to Europe. The company filed the intimation with BSE and NSE under SEBI Listing Regulations, citing family reasons. No successor has been appointed.NDTV ProfitFive Stocks To Buy Today, November 9: Alkem Labs, MTNL, Wockhardt And MoreMarket experts recommended buying Onesource Specialty Pharma, Alkem Laboratories, MTNL, Venus Pipes & Tubes, and Wockhardt, with targets implying upside of up to 24% from current market prices. The recommendations include specific entry levels and stop-losses, with Wockhardt's target suggesting the highest upside at 23.98%.ScanXOneSource Specialty Pharma gets USFDA VAI for Bengaluru sterile facilityOneSource Specialty Pharma received a USFDA Establishment Inspection Report with a Voluntary Action Indicated (VAI) classification for its Bengaluru sterile facility, following an inspection from June 22 to June 30, 2026. The VAI indicates cGMP violations requiring voluntary corrective actions, and the company reported Q2FY27 revenue of ₹5,162 million, up 37% year-on-year.MintOneSource Specialty Pharma shares jump 14% after Q2 results; recover 50% from recent lows | Stock Market NewsOneSource Specialty Pharma shares rose nearly 14% on October 27 after Q2 results showed revenue of ₹516.2 crore, up 37% year-on-year. EBITDA rose 53% to ₹163.3 crore, and adjusted PAT jumped 1,372% to ₹93.7 crore. The company expects DDC capacity to triple by FY28.Investing.comOneSource Q2FY27 slides: DDC capacity drives 53% EBITDA growthOneSource Specialty Pharma reported Q2FY27 revenue of ₹5,162 million ($54.2 million), up 37% year-over-year, and EBITDA of ₹1,633 million ($17.2 million), up 53%. Shares rose 13.78% to $1,589.8, and the company reaffirmed its fiscal 2028 targets of $400 million organic revenue and a 40% EBITDA margin.Business & FinancialOneSource Announces Strong Q2FY27 Results Revenue up 37% YoY and EBITDA up 53% YoYOneSource Specialty Pharma reported Q2FY27 revenue of ₹5,162 million, up 37% year-over-year, and EBITDA of ₹1,633 million, up 53% year-over-year. Adjusted PAT rose 109% to ₹937 million, and the CEO cited new DDC capacity and a second cartridge line as growth drivers.CNBCTV18Onesource Specialty Pharma Q2 Results: Stock jumps 8% on strong operating performance, revenue growth - CNBC TV18Onesource Specialty Pharma reported Q2 revenue of ₹516.2 crore, up 37.4% year-on-year, and net profit of ₹57.4 crore, up from ₹10.4 crore. EBITDA rose 53% to ₹163.2 crore, and margins expanded to 31.6%. The company guided FY2028 organic revenue to $400 million and 40% EBITDA margin.TradingViewNews by CNBC TV18 on TradingView, 2026-10-27Onesource Specialty Pharma reported Q2 revenue of ₹516.2 crore, up 37.4% year-on-year, and net profit of ₹57.4 crore, up from ₹10.4 crore. EBITDA rose 53% to ₹163.2 crore, and EBITDA margin expanded to 31.6%. The stock surged 8% on Tuesday.TradingViewONESOURCE: Q2 revenue reached Rs 5,162m as PAT rose to Rs 575mONESOURCE reported Q2 consolidated revenue of Rs 5,162.42m and PAT of Rs 574.84m, with H1 revenue reaching Rs 9,652.65m and PAT Rs 824.81m. H1 operating cash flow remained negative, and the legacy Sputnik vaccine litigation continues under arbitration.Business StandardIndia Ratings and Research upgrades LT rating of Onesource Specialty Pharma to 'A'India Ratings and Research upgraded Onesource Specialty Pharma's long-term credit rating to 'IND A' from 'IND A-' with a positive outlook. The upgrade reflects the company's transition to a commercial supply-led model, driven by successful GLP-1 supplies and strengthened revenue visibility. India Ratings anticipates improved profitability and cash flow generation due to expanded capacity utilization.